Re: [IAC#RG] New DRDO Drug 2-DG is based on Acharya Balkrishna’s research

So this drug has been in experimentation for very long in INMAS-DRDO. Even many years before COVID came into existence, DRDO was using it as an radioprotective drug against tumor cells. 

Check the author list, after Acharya Balkrishna, another name is Dr. Pallavi Thakur, who is an ex-INMAS fellow. Also, you may find the research articles published by INMAS in the given link.

https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=2+deoxy+d+glucose+INMAS&btnG=.  Patanjali has done some simulation work on the effectiveness of 2-Deoxy D Glucose, but not actual clinical trials. 

 

Kanishka Sharma, Ph.D.

---

From: indiaresists-request@lists.riseup.net <indiaresists-request@lists.riseup.net> on behalf of Pankaj Jangid <pankaj@codeisgreat.org>
Sent: Friday, May 14, 2021 10:25 AM
To: indiaresists@lists.riseup.net <indiaresists@lists.riseup.net>
Subject: [IAC#RG] New DRDO Drug 2-DG is based on Acharya Balkrishna's research

 

I started to dig about this new drug 2-DG, which was launched last week
by DRDO and Dr. Reddy's. This drug is claimed to reduce the oxygen
demand by a body infected with covid-19.

Reading more on this, I found that this is actually based on a research
paper by Acharya Balkrishna et al. of Patanjali Ayurveda. Here is the
original paper published on the aggregator ResearchGate:

https://www.researchgate.net/publication/340332773_Glucose_antimetabolite_2-Deoxy-D-Glucose_and_its_derivative_as_promising_candidates_for_tackling_COVID-19_Insights_derived_from_in_silico_docking_and_molecular_simulations

--
Regards,
Pankaj Jangid